AC Immune (ACIU) News Today

Summary for AC Immune (NASDAQ:ACIU)

• Positive Sentiment: Leerink Partners maintained a Buy rating and highlighted the company’s promising pipeline and strong financial position, underpinning a positive long-term outlook. AC Immune SA: Promising Pipeline and Strong Financial Position Justify Buy Rating
• Positive Sentiment: Leerink Partners raised its Q3 2025 EPS estimate to a narrower loss of ($0.25) from ($0.26), reflecting improving near-term profitability expectations.
• Positive Sentiment: Leerink Partners also boosted its FY2027 EPS forecast to $0.15 from $0.13, signaling growing confidence in AC Immune’s longer-term earnings potential.
• Neutral Sentiment: AC Immune reported Q2 2025 financial progress, detailing operational updates and cash runway metrics. AC Immune Reports Q2 2025 Financial Progress
• Negative Sentiment: HC Wainwright cut its FY2025 EPS estimate to a larger loss of ($0.87) from ($0.85), suggesting slightly weaker near-term profitability than previously expected.
• Negative Sentiment: HC Wainwright also trimmed its FY2027 EPS forecast to $0.10 from $0.12, reflecting tempered growth expectations. FY2027 EPS Estimates for AC Immune Reduced by HC Wainwright